Overcoming Regulatory Challenges and Optimizing Pharmaceutical Product Launches – inConversation with Regina Dawkins
Regina Dawkins, a seasoned expert in pharmaceutical supply chains and regulatory compliance, shares her insights on the critical challenges of entering the EU market. She discusses the complexities of navigating diverse healthcare regulations, building resilient supply chains, and the strategic steps necessary for successful product launches. Ms Dawkins also highlights the importance of early planning, expert engagement, and compliance with stringent EU standards to optimize market entry and accelerate launch timelines, providing a comprehensive guide for pharmaceutical companies looking to expand into the EU.
What are the most significant hurdles to overcome when launching a product across the diverse healthcare systems of the EU?
One of the biggest challenges when launching a product in the EU is understanding the complex regulatory landscape. Besides the overarching European legislation, each country has its own national requirements for the supply of medicinal products. To enter the market, companies need not just an Approved Marketing Authorisation but also a licensed supply chain, including authorisations for importation, batch release, and distribution (European Commission, “Regulatory Framework for Medicinal Products in Europe”) .
How can pharmaceutical companies effectively navigate the complex regulatory landscape and secure market access in the EU?
Navigating the EU’s regulatory framework requires early planning. This includes selecting the best Marketing Authorisation route—whether centralised, decentralised, or national (EMA, “How to Obtain a Marketing Authorisation in the EU”) . Mapping your supply chain is also essential, from the point of entry into the EU to your target launch markets and fiscal routes. Engaging early with experts in regulatory, pharmacovigilance, and quality compliance can help identify specific requirements, especially in more complex markets like the UK and Switzerland (EudraLex Volume 4, “Good Manufacturing Practice (GMP) Guidelines”) .
What strategies are essential for building a resilient and efficient supply chain to support successful product launches in the EU?
To build a strong supply chain, start with early planning to ensure compliance at every step. All parties involved should be fully authorised and experienced in their roles. Verifying EU GMP compliance for manufacturing, packaging, and testing processes is critical (EudraLex Volume 4, “Good Manufacturing Practice (GMP) Guidelines”) . Working closely with regulatory and quality teams from the beginning can help set up a compliant and reliable supply chain.
What key factors determine the timeline for a successful EU product launch, and how can these be optimized to accelerate market entry?
A well-thought-out launch strategy is key to a timely market entry in the EU. Key factors include:
- Deciding on the Marketing Authorisation site
- Choosing launch countries
- Meeting local representation requirements (regulatory, pharmacovigilance, quality)
- Ensuring proper labelling and packaging requirements, including serialization
- Planning a wholesale authorisation strategy
- Addressing pricing and reimbursement
Focusing on these elements early and working with experts can help streamline the process and reduce time to market.
What role does digital innovation play in transforming commercialization strategies and enhancing product launch success in the EU?
Digital innovation doesn’t play a direct role in transforming commercialization strategies in the EU, largely because of the intricacies and stringent nature of the European regulatory landscape. While digital tools can support efficiency in certain areas, they cannot fundamentally alter the highly regulated processes required for market access.
How can patient-centricity be integrated into the product launch process to improve outcomes and build long-term success?
The European Union has established harmonized regulations for wholesale distribution, Good Manufacturing Practices (GMP), and Good Distribution Practices (GDP) through key pharmaceutical legislation, including Directive 2001/83/EC i, Directive 2003/94/EC ii, and Guidelines 2013/C 343/01 iii. These regulations have significantly improved patient access to medicines by streamlining compliance requirements across member states. By integrating these standards early in your launch strategy and ensuring compliance with EU pharmaceutical legislation, companies can enhance their chances of securing a successful Marketing Authorisation, ensuring a smoother and faster pathway to market.
Can you share a successful EU product launch case study, highlighting the key factors that contributed to its success?
A successful example is the launch of a product into major EU markets by a US company. Key factors included early supply chain planning and understanding both EU and local regulations. Establishing a dedicated EU entity as the Marketing Authorisation Holder and obtaining the necessary distribution licenses were crucial steps that helped navigate regulatory challenges and achieve a smooth market entry.
- i Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
- ii Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use
- iii Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use
About the expert
Regina Dawkins is an experienced director with over 30 years in the pharmaceutical industry, specializing in APIs, manufacturing, storage, distribution, and transportation across the UK and Ireland. With in-depth knowledge of UK, EU, and US GMP regulations and a proven track record in compliance evaluations, she has successfully supported product launches across global markets, including Europe, the US, and emerging regions. Regina is a recognized expert in managing complex supply chains, partnering with third-party organizations, and ensuring seamless compliance in highly regulated environments.
Disclaimer:
This article is intended to communicate PharmaLex’s capabilities which are backed by the author’s expertise. However, PharmaLex, its parent, Cencora, strongly encourage readers to review the references provided with this article and all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto as the article may contain certain marketing statements and does not constitute legal advice.
The views and opinions expressed in this article are those of the expert, and do not necessarily reflect the official policy or position of the platform. The platform does not endorse or take responsibility for the content and encourages readers to seek professional advice before making any decisions based on the information provided.
